208 related articles for article (PubMed ID: 14595039)
41. Data required for the evaluation of newborn screening programmes.
Liebl B; Nennstiel-Ratzel U; Roscher A; von Kries R
Eur J Pediatr; 2003 Dec; 162 Suppl 1():S57-61. PubMed ID: 14615887
[TBL] [Abstract][Full Text] [Related]
42. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
DiSantostefano RL; Biddle AK; Lavelle JP
Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
[TBL] [Abstract][Full Text] [Related]
43. Enzymatic diagnosis of medium-chain acyl-CoA dehydrogenase deficiency by detecting 2-octenoyl-CoA production using high-performance liquid chromatography: a practical confirmatory test for tandem mass spectrometry newborn screening in Japan.
Tajima G; Sakura N; Yofune H; Nishimura Y; Ono H; Hasegawa Y; Hata I; Kimura M; Yamaguchi S; Shigematsu Y; Kobayashi M
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Sep; 823(2):122-30. PubMed ID: 16046200
[TBL] [Abstract][Full Text] [Related]
44. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin.
Shorr AF; Susla GM; Kollef MH
Crit Care Med; 2004 Jan; 32(1):137-43. PubMed ID: 14707572
[TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness of inhaled nitric oxide for the management of persistent pulmonary hypertension of the newborn.
Lorch SA; Cnaan A; Barnhart K
Pediatrics; 2004 Aug; 114(2):417-26. PubMed ID: 15286225
[TBL] [Abstract][Full Text] [Related]
46. Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis.
Ladabaum U; Scheiman JM; Fendrick AM
Am J Med; 2003 May; 114(7):546-54. PubMed ID: 12753878
[TBL] [Abstract][Full Text] [Related]
47. [Analysis of clinical characteristics and ACADM gene variants in four children with Medium chain acyl-CoA dehydrogenase deficiency].
Xiao M; Xie Z; Liu J; Li X; Zhang Q; Zhang Z; Li D
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Jul; 40(7):787-794. PubMed ID: 37368378
[TBL] [Abstract][Full Text] [Related]
48. Acylcarnitine profiles during carnitine loading and fasting tests in a Japanese patient with medium-chain acyl-CoA dehydrogenase deficiency.
Yokoi K; Ito T; Maeda Y; Nakajima Y; Ueta A; Nomura T; Koyama N; Kato I; Suzuki S; Kurono Y; Sugiyama N; Togari H
Tohoku J Exp Med; 2007 Dec; 213(4):351-9. PubMed ID: 18075239
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness of routine screening for critical congenital heart disease in US newborns.
Peterson C; Grosse SD; Oster ME; Olney RS; Cassell CH
Pediatrics; 2013 Sep; 132(3):e595-603. PubMed ID: 23918890
[TBL] [Abstract][Full Text] [Related]
50. Management Principles for Acute Illness in Patients With Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency.
McGregor TL; Berry SA; Dipple KM; Hamid R;
Pediatrics; 2021 Jan; 147(1):. PubMed ID: 33372121
[TBL] [Abstract][Full Text] [Related]
51. The cost-effectiveness of screening the U.S. blood supply for West Nile virus.
Custer B; Busch MP; Marfin AA; Petersen LR
Ann Intern Med; 2005 Oct; 143(7):486-92. PubMed ID: 16204161
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness analysis of artificial intelligence-based diabetic retinopathy screening in rural China based on the Markov model.
Li H; Li G; Li N; Liu C; Yuan Z; Gao Q; Hao S; Fan S; Yang J
PLoS One; 2023; 18(11):e0291390. PubMed ID: 37971984
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness and implications of newborn screening for prolongation of QT interval for the prevention of sudden infant death syndrome.
Zupancic JA; Triedman JK; Alexander M; Walsh EP; Richardson DK; Berul CI
J Pediatr; 2000 Apr; 136(4):481-9. PubMed ID: 10753246
[TBL] [Abstract][Full Text] [Related]
54. A newborn Screening Programme for Inborn errors of metabolism in Galicia: 22 years of evaluation and follow-up.
Couce ML; Bóveda MD; Castiñeiras DE; Vázquez-Mosquera ME; Barbosa-Gouveia S; De Castro MJ; Iglesias-Rodríguez AJ; Colón C; Cocho JA; Sánchez P
Orphanet J Rare Dis; 2024 May; 19(1):202. PubMed ID: 38760795
[TBL] [Abstract][Full Text] [Related]
55. Incidence of medium-chain acyl-CoA dehydrogenase deficiency in Canada using the Canadian Paediatric Surveillance Program: Role of newborn screening.
Prasad C; Speechley KN; Dyack S; Rupar CA; Chakraborty P; Kronick JB
Paediatr Child Health; 2012 Apr; 17(4):185-9. PubMed ID: 23543005
[TBL] [Abstract][Full Text] [Related]
56. Newborn mass screening versus selective investigation: benefits and costs.
Pollitt RJ
J Inherit Metab Dis; 2001 Apr; 24(2):299-302. PubMed ID: 11405348
[TBL] [Abstract][Full Text] [Related]
57. Modeling the impact of genetic screening technologies on healthcare: theoretical model for asthma in children.
Gutiérrez de Mesa E; Hidalgo I; Christidis P; Ciscar JC; Vegas E; Ibarreta D
Mol Diagn Ther; 2007; 11(5):313-23. PubMed ID: 17963419
[TBL] [Abstract][Full Text] [Related]
58. Improving nurse-to-patient staffing ratios as a cost-effective safety intervention.
Rothberg MB; Abraham I; Lindenauer PK; Rose DN
Med Care; 2005 Aug; 43(8):785-91. PubMed ID: 16034292
[TBL] [Abstract][Full Text] [Related]
59. A computer simulation model for cost-effectiveness analysis of mass screening for Type 2 diabetes mellitus.
Chen TH; Yen MF; Tung TH
Diabetes Res Clin Pract; 2001 Nov; 54 Suppl 1():S37-42. PubMed ID: 11580967
[TBL] [Abstract][Full Text] [Related]
60. Newborns with suspected occult spinal dysraphism: a cost-effectiveness analysis of diagnostic strategies.
Medina LS; Crone K; Kuntz KM
Pediatrics; 2001 Dec; 108(6):E101. PubMed ID: 11731628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
